Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia ...
As part of proposed merger, Pulmatrix (PULM) currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its ...
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback